Clinical Trial

Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis

Name: Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis — clinical trial record (NCT07401121)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: KOANEWA

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000.

Trial Details

NCT Number	NCT07401121
Lead Sponsor	Celosia Therapeutics Pty Ltd Collaborators: Novotech (Australia) Pty Limited
Conditions	ALS (Amyotrophic Lateral Sclerosis)
Enrollment	15 participants
Start Date	2026-01-12
Primary Completion	2027-12 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-02-10